Sun Pharmaceutical has collaborated with Israels Technion University, to develop anti-cancer drugs. Both have entered into a worldwide research and license agreement, as quoted in Sun Pharmas official statement.

“The Technion is delighted to partner with Sun Pharma to advance this project through a pre-clinical development process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical companies demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship between the Technion and Sun Pharma”, added Ciechanover and Binah.

This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline. Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs said Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.